MAPK3 and head and neck squamous cell carcinoma: In the same study, the authors investigated the involvement of ERK1/2-NANOG signaling on tumor growth and metastasis and found that ERK1/2-NANOG inhibition may reverse CSC phenotypes and have potential to reduce tumor progression and metastasis in HNSCC patients.